Combating Antimicrobial Resistance: Untapped mAb Potential The PrIMAVeRa project develops a platform to evaluate how mAbs can combat AMR by reducing antibiotic use and providing strategies for policymakers.

EVI-led #PrIMAVeRa_AMR project has published an article on BioProcess International on the use of monoclonal antibodies to tackle #AMR, & how PrIMAVeRa's open-access digital platform can support evidence-based public health decisions.

📃 www.bioprocessintl.com/monoclonal-a...
@ihieurope.bsky.social

Ecraid joins the #PrIMAVeRa_AMR Consortium to accelerate #AMR modelling!

This strategic partnership is a powerful step forward in the fight against #AntimicrobialResistance.

👉🏽Learn more about this vital collaboration & its impact on public health: www.ecraid.eu/news/ecraid-...

#StopSuperbugs

Ecraid becomes the newest member of the PrIMAVeRa Consortium PrIMAVeRa welcomes Ecraid, the newest member of the project consortium.

🤝 The #PrIMAVeRa_AMR consortium welcomes its newest partner: the European Clinical Research Alliance on Infectious Diseases (@ecraid.bsky.social)!
🔗 Read more: www.primavera-amr.eu/post/ecraid-...
#EUfunded @ihieurope.bsky.social @ecraid.bsky.social

PrIMAVeRa Consortium holds Annual Meeting in Madrid Consortium partners of the PrIMAVeRa project met in Madrid from 06-07 November for the project’s fourth annual meeting.

#PrIMAVeRa_AMR project holds 4th annual meeting: discussing modelling impacts of vaccines & mAbs on #AMR, and sustainability of project outputs. Read more: www.primavera-amr.eu/post/primave...